Cite
Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017.
MLA
Yade, Mamadou Samb, et al. “Ex Vivo RSA and Pfkelch13 Targeted-Amplicon Deep Sequencing Reveal Parasites Susceptibility to Artemisinin in Senegal, 2017.” Malaria Journal, vol. 22, no. 1, May 2023, pp. 1–7. EBSCOhost, https://doi.org/10.1186/s12936-023-04588-1.
APA
Yade, M. S., Dièye, B., Coppée, R., Mbaye, A., Diallo, M. A., Diongue, K., Bailly, J., Mama, A., Fall, A., Thiaw, A. B., Ndiaye, I. M., Ndiaye, T., Gaye, A., Tine, A., Diédhiou, Y., Mbaye, A. M., Doderer-Lang, C., Garba, M. N., Bei, A. K., & Ménard, D. (2023). Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017. Malaria Journal, 22(1), 1–7. https://doi.org/10.1186/s12936-023-04588-1
Chicago
Yade, Mamadou Samb, Baba Dièye, Romain Coppée, Aminata Mbaye, Mamadou Alpha Diallo, Khadim Diongue, Justine Bailly, et al. 2023. “Ex Vivo RSA and Pfkelch13 Targeted-Amplicon Deep Sequencing Reveal Parasites Susceptibility to Artemisinin in Senegal, 2017.” Malaria Journal 22 (1): 1–7. doi:10.1186/s12936-023-04588-1.